2.1. Study Population
This study complied with the Helsinki Declaration and was approved by the institutional ethics committee of Fuwai Central China Cardiovascular Hospital, Zhengzhou University (Zhengzhou, China). All participants in the study provided written informed consent. This trial has been registered on the ClinicalTrials website (This study was a single-center study where 107 patients were enrolled from Fuwai Central China Cardiovascular Hospital. Of these, 99 patients were randomized after screening for inclusion and exclusion criteria over the period from October 2021 to January 2022. Randomization was performed using a computer-generated list and SPSS software (IBM SPSS 25.0; SPSS Inc., Armonk, NY). Eighty-two patients underwent a 6-month angiographic followup (